Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development SummitGlobeNewsWire • Monday
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration SymposiumGlobeNewsWire • 11/13/24
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” ProgramGlobeNewsWire • 11/05/24
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16thGlobeNewsWire • 10/09/24
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/04/24
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/13/24
Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 InhibitorGlobeNewsWire • 07/15/24
Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society SymposiumGlobeNewsWire • 07/03/24
Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain SocietyGlobeNewsWire • 06/04/24
Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24GlobeNewsWire • 05/29/24
Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/13/24
Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14thGlobeNewsWire • 05/10/24
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer TherapyGlobeNewsWire • 04/23/24
Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern TimeGlobeNewsWire • 04/22/24
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business UpdateGlobeNewsWire • 03/25/24
Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation ChallengeGlobeNewsWire • 03/12/24
Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20thAccesswire • 02/15/24
Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral NeuropathyGlobeNewsWire • 01/23/24
Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12GlobeNewsWire • 01/08/24
Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in GermanyGlobeNewsWire • 12/05/23
Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in GermanyGlobeNewsWire • 11/30/23
Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/13/23
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain CancersGlobeNewsWire • 11/09/23
Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023GlobeNewsWire • 11/02/23
Principal Investigator of Artelo's CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and CachexiaGlobeNewsWire • 10/04/23